Akèy › Leksemi limfoblastik egi › Texas › Houston
Etid klinik pou Leksemi limfoblastik egi nan Houston, TX
28 etid pou Leksemi limfoblastik egi ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- UT MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Ap rekriteFaz 1
- Texas Children's Hospital, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
- Baylor Texas Children's Hospital, Houston
A Study of CTD402 in T-ALL/LBL Patients
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Ap rekriteEtid obsèvasyon
- Baylor College of Medicine Houston, Houston
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
Ap rekriteFaz 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Ap rekriteFaz 1/2
- Research Site, Houston
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Ap rekriteFaz 1/2
- Research Site, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
Ap rekriteFaz 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Ap rekriteFaz 1/2
- MD Anderson, Houston
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Ap rekriteEtid obsèvasyon
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ap rekriteFaz 3
- Ascentage Investigative Site #1501, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- MDACC, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- MD Anderson, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Etid Leksemi limfoblastik egi nan lòt vil
- New York City, NY24 etid
- Baldwin Park, CA21 etid
- Seattle, WA21 etid
- Chicago, IL19 etid
- Atlanta, GA19 etid
- Philadelphia, PA16 etid
- Memphis, TN16 etid
- Washington, DC16 etid
- Boston, MA15 etid
- Los Angeles, CA14 etid
- Durham, NC13 etid
- Mountain View, CA13 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.